Triple-agonist retatrutide hits new weight loss highs.
In: Family Practice News, 2023-06-01, S. 1-4
Online
Zeitungsartikel
Zugriff:
The article focuses on the effectiveness of retatrutide, a triple-agonist molecule that targets weight loss through multiple mechanisms. The phase 2 studies showed that retatrutide produced significant weight loss, including an average drop of 24 percent in bodyweight in individuals with overweight or obesity and no type 2 diabetes, as well as an average reduction of 17 percent in individuals with overweight or obesity and type 2 diabetes.
Titel: |
Triple-agonist retatrutide hits new weight loss highs.
|
---|---|
Autor/in / Beteiligte Person: | Zoler, Mitchel L. |
Link: | |
Zeitschrift: | Family Practice News, 2023-06-01, S. 1-4 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
ISSN: | 0300-7073 (print) |
Schlagwort: |
|
Sonstiges: |
|